Is your medical device’s biological evaluation threatening your regulatory timeline? Missing evidence, poorly justified testing and late-stage documentation gaps can result in additional work, avoidable costs and difficult questions during conformity assessment. The longer these issues remain unresolved, the harder they can become to address without disrupting development plans.

Manufacturers need a clear, risk-based approach to Biocompatibility that establishes what evidence is available, what is still missing and whether further testing is scientifically necessary. Choosing an experienced biocompatibility consultant can make that process more focused and manageable.

At Billev Pharma East, we help medical device manufacturers prepare Biological Evaluation Plans (BEPs) and Biological Evaluation Reports (BERs), assess existing scientific data and address relevant toxicological risks. Our specialists help you build a defensible biological safety rationale without treating additional laboratory testing as the automatic first step.

What must medical device manufacturers do to demonstrate biological safety?

Medical device manufacturers must identify and evaluate relevant biological risks and document why their devices are acceptably safe for their intended use. EU MDR Annex I addresses chemical, physical and biological properties, while Annex II requires appropriate supporting information in technical documentation. A biological evaluation should therefore be part of the device’s wider risk management process, rather than a collection of separate laboratory reports.

The starting point is to understand the finished device. Its materials, body-contact characteristics, intended purpose, manufacturing residues and potential patient exposure can all influence which biological hazards need evaluation. Manufacturers must then review relevant evidence, establish where it is adequate and explain where uncertainty remains. Applicable parts of the ISO 10993 series support this structured, risk-based approach.

These conclusions also need to be consistent with the broader technical documentation for the device. For further context, see our guidance on the medical device technical file.

A Biological Evaluation Plan (BEP) sets out the intended assessment, including the relevant evidence and gaps to be addressed. A Biological Evaluation Report (BER) draws together the available information and explains the scientific basis for the biological safety conclusions. The adequacy of this documentation depends on the device itself; reports from similar materials or previous products cannot simply be transferred without justification.

For companies lacking dedicated internal resources, an experienced biocompatibility consultant can help establish a proportionate evaluation strategy and avoid discovering critical evidence gaps only when technical documentation is already under review.

How can Billev Pharma East help you overcome biocompatibility challenges?

At Billev Pharma East, we turn complex biological safety questions into practical, evidence-based decisions. Our biocompatibility consultant supports manufacturers who need a coherent evaluation strategy, stronger justification for existing data or reliable preparation of biological evaluation documentation. We focus on what the device actually requires, rather than recommending extensive new testing by default.

Our work centres on two key deliverables: the Biological Evaluation Plan (BEP) and the Biological Evaluation Report (BER). We examine the device’s intended use, material and manufacturing information, relevant biological endpoints, published literature and available test results. Where appropriate, we integrate toxicological risk assessment to clarify potential exposure-related concerns and support the overall conclusions.

This approach can be particularly useful when technical files contain evidence collected at different stages of development, or when manufacturers are uncertain whether historical data remain applicable. We help identify where the scientific rationale is strong, where gaps remain and where additional information may genuinely be needed. Clearer decisions at this stage can prevent duplicated effort later.

Our in-house specialist brings toxicological expertise to the biological evaluation process. Whether you are preparing documentation for an initial conformity assessment, updating a current evaluation or responding to a specific technical concern, we can help you establish a traceable scientific justification and determine which evidence needs to be addressed next.

Contact our specialists to discuss your device, existing biological safety evidence and documentation needs, and identify the most appropriate next steps for your evaluation.

What should you consider when preparing a biological evaluation?

A strong biological evaluation begins before any new laboratory tests are commissioned. Manufacturers should first determine how the finished device will contact the body, which materials and process-related substances may be present and what evidence is already available. Those decisions influence the biological endpoints to be addressed and the most appropriate way to address them.

Data quality matters as much as data quantity. A historical test report may be useful, but only if its test article, manufacturing conditions and intended exposure are sufficiently relevant to the current device. Likewise, scientific literature can support a justification when its applicability is critically assessed. Unsupported assumptions about material equivalence can leave important questions unanswered.

Chemical characterisation and toxicological information may help clarify risks that cannot be fully understood from basic material descriptions alone. Any remaining uncertainties should be documented and evaluated in the context of the overall risk management process. A suitable BEP helps establish this reasoning early; the BER should then communicate the assessment and its conclusions clearly.

Working with a biocompatibility consultant gives manufacturers access to a critical review of available evidence before deciding on further work. At Billev Pharma East, we help define the evidence strategy around your individual device so that assessment activities serve a clear scientific and regulatory purpose.

Can a biocompatibility consultant help you avoid unnecessary testing costs?

Yes. A biocompatibility consultant can help reduce unnecessary testing expenditure by assessing whether existing evidence sufficiently addresses the relevant biological risks. New tests may be necessary, but they should follow an informed review of what is already known about the finished device, not replace that review.

For some devices, well-documented historical results, appropriate material and chemical information, and relevant published research can answer questions that might otherwise trigger another testing programme. The usefulness of these sources depends on their quality and on whether they genuinely represent the device under evaluation. A report generated for a different contact duration or a materially different manufacturing process may not be enough.

At Billev Pharma East, we review available documentation to identify evidence that can be retained, limitations that require further analysis and gaps that may justify additional testing. Our toxicological expertise supports the interpretation of chemical exposure information where relevant. This can help manufacturers distinguish essential work from activities that may not contribute meaningful new evidence.

The benefit is not a promise to remove required tests. It is a financially more considered approach: existing evidence is assessed before laboratory work is commissioned, helping teams allocate their testing budget to unresolved biological risks. When new tests are needed, their purpose and scope are clearer from the outset.

Why does toxicological expertise matter when selecting a biocompatibility consultant?

Toxicological expertise is especially valuable when the biological evaluation depends on understanding substances that may be released from a medical device and their potential effects on patients. A biocompatibility consultant who can interpret these issues is better placed to connect the available chemical evidence with the device’s intended use and biological risk profile.

Where chemical exposure questions are particularly complex, dedicated toxicology consultancy can complement the biological evaluation by supporting interpretation of relevant toxicological evidence.

Material specifications alone do not always reveal the full picture. Manufacturing, processing, cleaning or sterilisation may influence the substances associated with a finished device. Chemical characterisation information, where available and relevant, therefore needs to be interpreted in the context of potential exposure and toxicological significance rather than treated as an isolated dataset.

At Billev Pharma East, our in-house specialist contributes toxicological expertise to biological evaluation planning and reporting. We critically assess the evidence, examine remaining uncertainties and integrate relevant toxicological findings into a coherent biological safety argument. That can be important where manufacturers need to explain why existing information is sufficient or why further assessment is warranted.

For a manufacturer choosing external support, this expertise helps turn chemical findings into an assessment of potential patient exposure and clinical relevance, rather than simply summarising laboratory reports. The resulting rationale is easier to explain when questions arise during development or regulatory review.

When should you involve a biocompatibility consultant in your medical device project?

The ideal time to engage a biocompatibility consultant is at the beginning of medical device development, well before the device is ready for conformity assessment and CE certification. Biological safety should be considered from the early design stages, allowing manufacturers to identify potential risks, define evidence requirements and plan the necessary evaluation activities before critical development decisions are finalised.

A Biological Evaluation Plan (BEP) should be established early in development and include a scientifically justified testing strategy. Based on the device’s intended use, materials and anticipated body contact, the BEP identifies relevant biological risks, evaluates existing evidence and defines which additional assessments or tests are needed. This allows manufacturers to integrate biocompatibility activities into their development timelines rather than addressing biological safety only when technical documentation is being finalised.

Delaying biological evaluation until the certification stage can lead to unexpected testing requirements, costly design changes and regulatory delays. Identifying potential issues early provides an opportunity to address them while design and material choices can still be adjusted, reducing the risk of additional work later.

At Billev Pharma East, we support manufacturers from the early development stages through the preparation of Biological Evaluation Plans, the assessment of scientific evidence and the subsequent preparation of Biological Evaluation Reports (BERs). By involving our experts early, you can establish a clear biological safety strategy, make informed testing decisions and approach conformity assessment with greater confidence.

Frequently asked questions about biocompatibility consulting

Ready to choose the right biocompatibility consultant for your device?

Choosing the right biocompatibility consultant can help your team make better use of existing evidence, avoid unnecessary testing and prepare a more convincing biological evaluation. The value lies in sound scientific judgement, clear documentation and an assessment strategy matched to your device rather than a standardised testing checklist.

At Billev Pharma East, we combine biological evaluation planning, BER preparation and in-house toxicological expertise to support manufacturers facing demanding documentation and conformity assessment requirements. If you are starting a new evaluation, revising an existing report or trying to resolve an evidence gap, we can help define the next practical step.

Contact Billev Pharma East to discuss your device, review the evidence you already have and identify the next steps towards a scientifically justified biological evaluation.

Sources: 1 – European Parliament and Council of the European Union. (2017). Regulation (EU) 2017/745 on medical devices (EU MDR), Annex I and Annex II, 2 – International Organization for Standardization (ISO). (2025). ISO 10993-1:2025 – Biological evaluation of medical devices – Part 1: Requirements and general principles for the evaluation of biological safety within a risk management process, 3 – International Organization for Standardization (ISO). (2023). ISO 10993-17:2023 – Biological evaluation of medical devices – Part 17: Toxicological risk assessment of medical device constituents, 4 – International Organization for Standardization (ISO). (2020). ISO 10993-18:2020 – Biological evaluation of medical devices – Part 18: Chemical characterization of medical device materials within a risk management process.